- Raw materials
- Vitamin D analogues
- Previtamin D(3)
Previtamin D(3) API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Previtamin D(3) | CAS No: 1173-13-3 | GMP-certified suppliers
A medication that supports bone health and calcium regulation by serving as a vital precursor in the metabolic synthesis of active vitamin D compounds.
Therapeutic categories
Product Snapshot
- Previtamin D(3) is formulated as an oral small molecule tablet with a film-coated finish
- It is primarily indicated for research and experimental use related to vitamin D metabolic pathways
- Currently, Previtamin D(3) holds an experimental status in the US market and is not yet approved by regulatory authorities
Clinical Overview
While previtamin D3 itself is not clinically indicated or approved for therapeutic use, it plays a critical biochemical role as an essential precursor in vitamin D metabolism. Released vitamin D3 undergoes hepatic 25-hydroxylation to form 25-hydroxyvitamin D3, the major circulating form, followed by renal 1α-hydroxylation to generate the biologically active hormone, 1,25-dihydroxyvitamin D3 (calcitriol). These active metabolites regulate calcium and phosphate homeostasis and influence bone mineralization.
The pharmacokinetic profile of previtamin D3 entails rapid thermal isomerization to vitamin D3 after synthesis in the skin. It is lipophilic and membrane-associated, consistent with its classification as a membrane lipid and sterol derivative. The compound itself is not typically measured or administered but is recognized for its role in the photobiological production of vitamin D.
Safety and toxicity profiles for isolated previtamin D3 are not established due to its experimental status and transient physiological existence. The safety considerations of vitamin D metabolites overall relate to hypervitaminosis D, characterized by hypercalcemia and associated complications.
No pharmaceutical brands market previtamin D3 as an API for direct use. Its relevance is primarily within biochemical and photobiological research contexts rather than clinical application.
For sourcing and quality assurance, procurement of precursors such as previtamin D3 should ensure high purity and stability, considering its photosensitive and thermally labile nature. Compliance with applicable pharmacopeial standards and controlled storage conditions is essential to maintain chemical integrity for research or manufacturing purposes.
Identification & chemistry
| Generic name | Previtamin D(3) |
|---|---|
| Molecule type | Small molecule |
| CAS | 1173-13-3 |
| UNII | HDA46400N5 |
| DrugBank ID | DB15614 |
Formulation & handling
- Previtamin D(3) is a small molecule intended for oral administration primarily in tablet form.
- Due to high lipophilicity (LogP 7.07) and very low water solubility, formulation strategies should focus on enhancing bioavailability.
- Stability in aqueous environments and potential degradation under light exposure should be considered during handling and storage.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient (API) is approaching patent expiry in the US, leading to increased availability of generic versions and a transition towards a mature market with multiple suppliers. This shift typically results in expanded access and competitive pricing. |
|---|
| Markets | US |
|---|
Supply Chain
| Supply chain summary | The manufacturing and supply landscape for Previtamin D(3) in the US market includes originator companies that have developed branded formulations such as Calcemin and Calcemin Advance. These branded products have an established presence primarily in the US, with limited information on their availability in other regions. Patent expirations for Previtamin D(3) suggest the potential for existing or forthcoming generic competition within this market. |
|---|
Previtamin D(3) is a type of Vitamin D analogues
Vitamin D analogues belong to the pharmaceutical category of active pharmaceutical ingredients (APIs) and are widely used in the medical field. These analogues are synthetic compounds designed to mimic the effects of natural vitamin D, a vital nutrient for human health. Vitamin D plays a crucial role in maintaining proper bone health, regulating calcium and phosphorus levels, and supporting the immune system.
Pharmaceutical companies produce various types of vitamin D analogues, each with distinct properties and applications. These analogues are designed to target specific receptors in the body, mimicking the actions of natural vitamin D. By interacting with these receptors, vitamin D analogues can effectively regulate calcium absorption and metabolism, promoting optimal bone health.
One of the significant advantages of using vitamin D analogues as APIs is their enhanced stability and bioavailability compared to natural vitamin D. This allows for better control over dosage and ensures consistent therapeutic effects. Moreover, pharmaceutical-grade analogues undergo rigorous quality control measures to guarantee their purity, safety, and efficacy.
Medical professionals prescribe vitamin D analogues to patients with vitamin D deficiencies, osteoporosis, psoriasis, and other related conditions. These APIs are available in various formulations, including oral tablets, capsules, and topical creams, allowing for flexible and convenient administration.
In summary, vitamin D analogues are a vital category of pharmaceutical APIs widely used to address vitamin D deficiencies and related health conditions. Their synthetic nature, enhanced stability, and targeted actions make them an effective option for maintaining bone health and supporting overall well-being.
